• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Transmembrane Stem Factor Nanodiscs Enhanced Revascularization in a Hind Limb Ischemia Model in Diabetic, Hyperlipidemic Rabbits
Res Sq. 2023 Jun 16:rs.3.rs-2997323. doi: 10.21203/rs.3.rs-2997323/v1. Preprint.ABSTRACTTherapies to revascularize ischemic tissue have long been a goal for the treatment of vascular disease and other disorders. Therapies using stem cell factor (SCF), also known as a c-Kit ligand, had great promise for treating ischemia for myocardial infarct and stroke, however clinical development for SCF was stopped due to toxic side effects including mast cell activation in patients. We recently developed a novel therapy using a transmembrane form of SCF (tmSCF) delivered in lipid nanodiscs. In previous studies, we demonstrated tmSCF n...
Source: Cell Research - July 3, 2023 Category: Cytology Authors: Eri Takematsu Miles Massidda Gretchen Howe Julia Goldman Patricia Felli Lei Mei Gregory Callahan Andrew Sligar Richard Smalling Aaron Baker Source Type: research

A Novel Rat Model of Embolic Cerebral Ischemia Using a Cell-Implantable Radiopaque Hydrogel Microfiber
We present a novel rat model of focal infarct restricted to the middle cerebral artery territory using a radiopaque hydrogel microfiber positioned under fluoroscopic guidance. By comparing the use of stem cell-containing versus non-containing fibers in this stroke model, it would be possible to determine the efficacy of "pure" cell transplantation in treating stroke.PMID:36867349 | DOI:10.1007/s12975-023-01144-6
Source: Cell Research - March 3, 2023 Category: Cytology Authors: Teppei Komatsu Hiroki Ohta Naoki Takakura Junichi Hata Tomomichi Kitagawa Yuta Kurashina Hiroaki Onoe Hirotaka James Okano Yasuyuki Iguchi Source Type: research

Prevention of neointimal hyperplasia induced by an endovascular stent via intravenous infusion of mesenchymal stem cells.
CONCLUSIONS: Intravenous infusion of MSCs inhibited the inflammatory reaction to an implanted stent strut, and prevented progressive neointimal hyperplasia in the stented CCA and SCA in a porcine model. Thus, MSC treatment could attenuate the recurrence of cerebral ischemic events after stenting. PMID: 31585431 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - October 3, 2019 Category: Neurosurgery Authors: Nakazaki M, Oka S, Sasaki M, Kataoka-Sasaki Y, Onodera R, Komatsu K, Iihoshi S, Hiroura M, Kawaguchi A, Kocsis JD, Honmou O Tags: J Neurosurg Source Type: research

Stroke Dysbiosis Index (SDI) in Gut Microbiome Are Associated With Brain Injury and Prognosis of Stroke
Conclusions: We developed an index to measure gut microbiota dysbiosis in stroke patients; this index was significantly correlated with patients' outcome and was causally related to outcome in a mouse model of stroke. Our model facilitates the potential clinical application of gut microbiota data in stroke and adds quantitative evidence linking the gut microbiota to stroke. Introduction Ischemic stroke imposes a heavy burden on society, with 24.9 million cases worldwide (1). Although intravenous thrombolysis and endovascular treatment greatly improve some patients' prognosis, the prognosis for most pa...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

Outcomes in Children with Severe Vasculopathy from Sickle Cell Anemia after Treatment with Chronic Transfusion, Surgical Revascularization and/or Allogenic Hematopoetic Stem Cell Transplantation
Conclusions: The risk for cerebral infarction and/or vasculopathy progression after initiation of treatment with either chronic transfusion, HSCT or EDAS is still a major concern. Our data suggest HSCT and surgical revascularization with chronic transfusion provide the greatest benefit in reducing stroke risk and HSCT reduces risk for progression of a severe vasculopathy. Additional, large population studies are needed to clarify the risk.DisclosuresMajumdar: NIMHD: Research Funding. Campbell: Functional Fluitics: Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Membership on ...
Source: Blood - November 21, 2018 Category: Hematology Authors: Johnson, C. W., Majumdar, S., Campbell, A. D., Magge, S., Darbari, D. S., Webb, J., Diab, Y. A., Nickel, R. S., Speller-Brown, B., Carpenter, J., Abraham, A. Tags: 114. Hemoglobinopathies, Excluding Thalassemia-Clinical: Poster I Source Type: research

Enhanced Long-Term Brain Magnetic Resonance Imaging Evaluation of Children with Sickle Cell Disease after Hematopoietic Cell Transplantation
Sickle cell disease (SCD) is the most common cause of stroke in children. Strokes and “clinically silent” infarcts are caused by progressive sickle vasculopathy in large and small vessels [1-4], leading to SCD brain vasculopathy. Both stroke types can affect neurological and cognitive function starting early in childhood [1,2,5-9]. Stroke or stroke risk is a frequent indication f or pediatric SCD transplantation [10-12]. Based on several studies using brain magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA), hematopoietic stem cell transplantation (HCT) is believed to halt progression of vasculopathy [10,12-16].
Source: Biology of Blood and Marrow Transplantation - January 8, 2017 Category: Hematology Authors: Nancy S. Green, Monica Bhatia, Erica Y. Griffith, Mahvish Qureshi, Courtney Briamonte, Mirko Savone, Stephen Sands, Margaret T. Lee, Angela Lignelli, Adam M. Brickman Source Type: research

Intra-Arterial Stem Cell Therapy for a Persistent Vegetative State Patient: A DTI Analysis of Recovery (P6.066)
Conclusion Assessing minor neurological improvements in this patient remains challenging but advances in neuroimaging as an evaluating tool helps to detect those changes. Future assessments and imaging will be performed to better clarify the findings mentioned above.Disclosure: Dr. Ramdas has nothing to disclose. Dr. Guada has nothing to disclose. Dr. Pafford has nothing to disclose. Dr. Haussen has nothing to disclose. Dr. Pattany has nothing to disclose. Dr. Yavagal has received personal compensation for activities with Covidien/evV3 as a consultant and Steering Committee Member.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Ramdas, K., Guada, L., Pafford, R., Haussen, D., Pattany, P., Yavagal, D. Tags: Cerebrovascular Disease: Miscellaneous Interventions Source Type: research

De Novo Arteriovenous Malformation Growth Secondary to Implantation of Genetically Modified Allogeneic Mesenchymal Stem Cells in the Brain
CONCLUSION: The development of an AVM within a period of 3 years after implantation of the glucagon-like peptide-1–secreting mesenchymal stem cells suggests a possible relationship. This case exemplifies that further investigations are necessary to assess the safety of genetically modified cell lines for local biological drug delivery in the brain. ABBREVIATIONS: ALK1, activin-like kinase 1 AVM, arteriovenous malformation ENG, endoglin; GLP-1, glucagon-like peptide-1 GLP-1R, glucagon-like peptide-1 receptor MSC, mesenchymal stem cell
Source: Neurosurgery - March 22, 2016 Category: Neurosurgery Tags: Case Report Source Type: research